TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06785272
Drug: magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After initial therapy with the systemic CSs routinely used for acute asthma management at a given site, 3 treatments with inhaled salbutamol and ipratropium, eligible patients with PRAM ≥5 will, under the care of the research nurse, receive a 30-minute IV infusion of 75 mg/kg of Mg sulfate(maximum 2.0 g) \[experimental group\]
Study: NCT05060003
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab is provided by Genentech.
Study: NCT05060003
Drug: Tiragolumab
Normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiragolumab is provided by Genentech.
Study: NCT06247917
Drug: Fludarabine, Busulfan and Melphalan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Use Fludarabine, Busulfan and Melphalan as myeloablative conditioning regimen for untreated MDS-EB patients.
Study: NCT06632483
Drug: Vericiguat (Verquvo, BAY1021189)
Normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prescibed as per local label
Study: NCT05139680
Drug: tafamidis
Normalized name: Tafamidis
DrugBank: Tafamidis (DB11644)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80 or 61 milligrams (mg)
Study: NCT06510660
Drug: adebrelimab
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study was divided into two cohorts based on CPS score, with those with CPS scores ≥10 receiving induction therapy with adebrelimab alone and those with CPS scores \<10 receiving induction therapy with adebrelimab in combination with chemotherapy. At the end of the induction period, concurrent radiotherapy treatment was administered
Study: NCT05062174
Drug: Mifepristone 200 MG
Normalized name: mifepristone 200 MG
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orally, one time dosage of 200 mg
Study: NCT04589845
Drug: Entrectinib
Normalized name: ENTRECTINIB
DrugBank: Entrectinib (DB11986)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adults and pediatric participants with a BSA \>/= 1.51 m2: entrectinib will be self-administered by participants orally at home at a dose of 600 mg/day (three 200-mg capsules per day). Pediatric participants with a BSA \< 1.51 m2: entrectinib will be administered orally at home in mini-tablet formulation at a dose of 400 mg/day (BSA=1.11-1.50 m2) or 300 mg/day (BSA=0.81-1.10 m2) or 200 mg/day (BSA=0.51-0.80 m2) or 100 mg/day (BSA=0.43-0.50 m2).
Study: NCT04589845
Drug: Alectinib
Normalized name: Alectinib
DrugBank: Alectinib (DB11363)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Alectinib will be administered orally BID (twice a day) with food at a dosage of 600 mg (four 150-mg capsules).
Study: NCT04589845
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg for participants aged \>/=18 years, and 15 mg/kg (maximum 1200 mg) for participants aged \<18 years on Day 1 of each 21-day cycle.
Study: NCT04589845
Drug: Ipatasertib
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants \< 35 kg, 300 mg for participants \>/= 35 and \< 45 kg, 400 mg for those \>/= 45 kg orally QD, beginning of Cycle 1, on Days 1-21 of each 28-day cycle until the participant experiences disease progression, intolerable toxicity, or withdraws consent.
Study: NCT04589845
Drug: Trastuzumab emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab emtansine will be administered at 3.6 mg/kg by IV infusion every 21 days until disease progression or unacceptable toxicity. The dosage and administration method also applies for pediatric participants 12-17 years of age.
Study: NCT04589845
Drug: Idasanutlin
Normalized name: Idasanutlin
DrugBank: Idasanutlin (DB12325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idasanutlin will be administered at 250 mg QD (daily) PO for Days 1-5 of each 28-day cycle. Idasanutlin may be given without regard to meals and water can be given as often as necessary or desired. The daily doses should be administered 10-14 hours apart.~Note: Cohort G has been closed for enrollment.
Study: NCT04589845
Drug: Inavolisib
Normalized name: Inavolisib
DrugBank: Inavolisib (DB15275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDC-077 will be administered QD at a starting dose of 9 mg PO in repeated 28-day cycles. The dosage and administration method also applies for pediatric participants 12-17 years of age.
Study: NCT04589845
Drug: Belvarafenib
Normalized name: Belvarafenib
DrugBank: Belvarafenib (DB17568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belvarafenib will be administered at a dose 400 mg (PO) BID with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle.
Study: NCT04589845
Drug: Pralsetinib
Normalized name: pralsetinib
DrugBank: Pralsetinib (DB15822)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pralsetinib will be self-administered by participants orally at home (except on clinic days) on a continuous daily dosing regimen at a dose of 400 mg/day (four 100-mg capsules per day) for adult and pediatric patients ≥ 12 and \< 18 years of age. A treatment cycle consists of 4 weeks (28 days).
Study: NCT04589845
Drug: GDC-6036
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GDC-6036 will be self-administered by patients orally at home (except on clinic days) on a continuous daily dosing regimen for both adult and pediatric patients. A treatment cycle consists of 3 weeks (21 days).
Study: NCT00001126
Drug: Cidofovir
Normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04589845
Drug: Camonsertib
Normalized name: Camonsertib
DrugBank: Camonsertib (DB18888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camonsertib will be self-administered by patients orally at home (except on clinic days). A treatment cycle consists of 3 weeks and will be given on days 1-3 and days 8-10 of every 21-day cycle.
Study: NCT05543603
Drug: Lacer Clorhexidina Colutorio
Normalized name: Clorhexidina
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 ml 0,12% Chlorhexidine, one minute rinse
Study: NCT05543603
Drug: Distilled water
Normalized name: Distilled Water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml distilled water, one minute rinse
Study: NCT05488873
Drug: WST-057 Active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WST-057 Topical Solution
Study: NCT06357182
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given SC
Study: NCT06357182
Drug: Iadademstat
Normalized name: Iadademstat
DrugBank: ORY-1001 (DB16848)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06357182
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04322383
Drug: binimetinib
Normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Binimetinib will be given orally at a dose of 45mg BID continuously for 28-day cycles with no resting period between cycles.
Study: NCT06703177
Drug: SHR-1826
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1826
Study: NCT06703177
Drug: SHR-4642
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-4642
Study: NCT06703177
Drug: SHR-9839
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-9839
Study: NCT06703177
Drug: SHR-8068
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-8068
Study: NCT06703177
Drug: Bevacizumab Injection
Normalized name: bevacizumab Injection
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab Injection
Study: NCT06703177
Drug: Calcium Folinate Injection
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Calcium Folinate Injection
Study: NCT06703177
Drug: Adebrelimab Injection
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adebrelimab Injection
Study: NCT04843566
Drug: Antibiotic (prophylaxis)
Normalized name: STONE PROPHYLAXIS
DrugBank: Gramicidin D (DB00027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For men undergoing transrectal biopsy, antibiotic prophylaxis will be administered in accordance with guidelines from the American Urological Association (AUA).~No antibiotic prophylaxis will be administered for men undergoing transperineal biopsy.
Study: NCT04780568
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04780568
Drug: Tegavivint
Normalized name: Tegavivint
DrugBank: Tegavivint (DB17109)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT06526494
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral ingestion for 12 weeks
Study: NCT05906953
Drug: HG004
Normalized name: HG004
DrugBank: HG004 (DB18666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Medium dose High dose
Study: NCT06299098
Drug: Trevogrumab-Part A
Normalized name: Echinacea, aerial parts
DrugBank: Trevogrumab (DB15159)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV or SC in Part A
Study: NCT06299098
Drug: Trevogrumab-Part B and Part C
Normalized name: Echinacea, aerial parts
DrugBank: Trevogrumab (DB15159)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC in Part B, Part C
Study: NCT06299098
Drug: Garetosmab
Normalized name: Garetosmab
DrugBank: Garetosmab (DB16379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV in Part B
Study: NCT06204432
Drug: Sodium Citrate
Normalized name: Sodium Citrate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Those randomized to the Sodium Citrate arm will use 1 mL of 2.5% sodium citrate (3.5g/140 mL, pH 7.4, 298 mOsmol/L), 0.5 mL in each nostril, twice a day via an atomizer followed by olfactory training.
Study: NCT05741229
Drug: Nebulized nitroglycerine as adjunctive therapy
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with PPHN will have nebulized nitroglycerine as adjunctive therapy
Study: NCT00624741
Drug: Pergolide
Normalized name: Pergolide
DrugBank: Pergolide (DB01186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pergolide tablets should be initiated with a daily dosage of 0.05 mg for the first 2 days. The dosage should then be gradually increased by 0.1 or 0.15 mg/day every third day over the next 12 days of therapy. The dosage may then be increased by 0.25 mg/day every third day until an optimal therapeutic dosage is achieved.
Study: NCT06299098
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered SC in Part B and Part C
Study: NCT05154994
Drug: Belinostat
Normalized name: Belinostat
DrugBank: Belinostat (DB05015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06552234
Drug: Repotrectinib
Normalized name: Repotrectinib
DrugBank: Repotrectinib (DB16826)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repotrectinib 160 mg BID, until progression or unacceptable toxicity
Study: NCT05026866
Drug: Donanemab
Normalized name: Donanemab
DrugBank: Donanemab (DB16647)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT06299098
Drug: Matching Placebo-Trevogrumab
DrugBank: Trevogrumab (DB15159)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC in Part B and Part C
Study: NCT06299098
Drug: Matching Placebo-Garetosmab
DrugBank: Garetosmab (DB16379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV in Part B
Study: NCT05902533
Drug: Mitomycin c
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/m2 slow IV push Day 1 and 29
Study: NCT04932915
Drug: Niclosamide
Normalized name: niclosamide
DrugBank: Niclosamide (DB06803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Niclosamide is a broad spectrum, host targeting antiviral that inhibits viral replication (by neutralizing endosomal pH) and increases viral clearance (by increasing the autophagic flux). The niclosamide solution is administered directly to the nasal cavity via a nasal spray.
Study: NCT06222723
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone will be administered for 10 days. For the first 48 hours, dexamethasone will be given iv. After 48 hours, a switch to oral dexamethasone (same dosage) is permitted at the discretion of the study physician.
Study: NCT06222723
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin treatment will be administered iv for 10 days, as recommended in the Nigeria Centre for Disease Control and Prevention National Guidelines for LF Case Management.
Study: NCT06139575
Drug: Lutetium Lu 177 JH020002 Injection
Normalized name: lutetium Lu 177 dotatate Injection
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Lutetium Lu 177 JH020002 Injection every 6 weeks for a maximum of 6 doses. Doses range between 1.85 and 8.88 GBq (50-240 mCi)
Study: NCT05198934
Drug: Sotorasib
Normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sotorasib will be administered orally
Study: NCT05198934
Drug: Panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab will be administered as intravenous (IV) infusion
Study: NCT05198934
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib will be administered orally
Study: NCT05170269
Drug: BT097
Normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive BT097 200 U per kg of maternal body weight intravenously every 2 weeks until at least GW 17
Study: NCT06464055
Drug: Dose Expansion1
Normalized name: COOK MYOSITES AUTOLOGOUS MUSCLE DERIVED CELLS (AMDC) ARE EXPANDED (AMPLIFIED) THROUGH A TWO-PHASE MANUFACTURING PROCESS. THE EXPANSION IS CONSISTENT WITH ROUTINE CELL CULTURE PRACTICES FOR ADHERENT CELLS. DURING ADHERENT CELL CULTURE EXPANSION, CELLS REP
DrugBank: Iltamiocel (DB19059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: GQ1010 dose 1
Study: NCT06464055
Drug: Dose Expansion2
Normalized name: COOK MYOSITES AUTOLOGOUS MUSCLE DERIVED CELLS (AMDC) ARE EXPANDED (AMPLIFIED) THROUGH A TWO-PHASE MANUFACTURING PROCESS. THE EXPANSION IS CONSISTENT WITH ROUTINE CELL CULTURE PRACTICES FOR ADHERENT CELLS. DURING ADHERENT CELL CULTURE EXPANSION, CELLS REP
DrugBank: Iltamiocel (DB19059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: GQ1010 dose 2
Study: NCT06464055
Drug: Dose Expansion3
Normalized name: COOK MYOSITES AUTOLOGOUS MUSCLE DERIVED CELLS (AMDC) ARE EXPANDED (AMPLIFIED) THROUGH A TWO-PHASE MANUFACTURING PROCESS. THE EXPANSION IS CONSISTENT WITH ROUTINE CELL CULTURE PRACTICES FOR ADHERENT CELLS. DURING ADHERENT CELL CULTURE EXPANSION, CELLS REP
DrugBank: Iltamiocel (DB19059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: GQ1010 dose 3
Study: NCT05673200
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT05625737
Drug: Fruquintinib
Normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib will be administrated as 4mg orally, once daily for 2 weeks on/1 week off.
Study: NCT05625737
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab will be administrated as 200mg once every 3 weeks.
Study: NCT04685577
Drug: Nefopam
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam HCl inhibits the proliferation and viability of human mesenchymal fibroblasts with elevated β-catenin expression without affecting normal fibroblasts. Nefopam HCl primarily targets cells in which β-catenin is above normal physiologic levels. This threshold effect makes Nefopam HCl a good prospective therapeutic agent by limiting its effect to abnormal mesenchymal cells.Nefopam HCl has been found safe and effective for the reduction of dermal scarring following standardized human dermal wounds of critical depth that produces HTS in normal human volunteers Phase 1 study. In the current study, it is proposed that the concentration of the cream will be 3% and the timing of application will be delayed until after re-epithelialization at about 21 days to maximize the antiproliferative effects of NEFOPAM during the fibrotic/proliferative phase of healing.
Study: NCT06694948
Drug: pimicotinib capsules
Normalized name: Pimicotinib
DrugBank: Pimicotinib (DB18972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pimicotinib capsules
Study: NCT05796752
Drug: Memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cognition-enhancing medication
Study: NCT05846230
Drug: BI 1291583
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT05968430
Drug: lorundrostat
Normalized name: Lorundrostat
DrugBank: Lorundrostat (DB18957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, administered orally
Study: NCT05605548
Drug: MitoQ
Normalized name: Mitoquinone
DrugBank: Mitoquinone (DB05063)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MitoQ is a mitochondrial targeted antioxidant that can be obtained over-the-counter.
Study: NCT05502562
Drug: Oral semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the participant in this study.
Study: NCT05984121
Drug: Local ozon injections
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local ozone therapy is approximately 2-3 cc of medical ozone, ozone-resistant is realised by injecting subcutaneously or intramuscularly with injectors. Local ozone injection group at 0., 2. and 4. weeks with ultrasound guided medial Firstly 1.5 cc with a 25 gauge needle into the plantar fascia insertion in the plantar region 02 lidocaine injection in a sterile way and then (according to the weeks 3 cc ozone injection of 10, 15 and 20 pyg/ml will be made respectively.
Study: NCT05984121
Drug: Local dextroz prolotherapy injections
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose prolotherapy injection group under ultrasound guidance at weeks 0, 2 and 4 1.5 cc 30% dextrose solution and 1.5 cc 2 lidocaine mixture with a 25 gauge needle into the medial plantar region cc 2 lidocaine mixture will be made sterile with 3 cc 15% dextrose.
Study: NCT05407389
Drug: KT-301 (formerly US-APR2020)
Normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: KT-301 (formerly US-APR2020) will be administered orally at 2 capsules per day (a total dose of 90 Billion CFUs per day of the Live BioTherapeutic).
Study: NCT06577363
Drug: Maribavir
Normalized name: MARIBAVIR
DrugBank: Maribavir (DB06234)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maribavir tablets
Study: NCT06113640
Drug: levodopa-carbidopa
Normalized name: carbidopa / levodopa
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbidopa/levodopa, also known as levocarb and co-careldopa, is the combination of the two medications carbidopa and levodopa. It is primarily used to manage the symptoms of Parkinson's disease
Study: NCT06113640
Drug: Montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast and other CysLT1 antagonists are currently used as an adjuvant therapy for children and adults suffering from asthma. Other indications have been proposed and most evidence exists for the use of montelukast to treat allergic rhinitis, but its use in other inflammatory conditions, such as atherosclerosis and chronic obstructive pulmonary disease, have also been suggested.
Study: NCT06453044
Drug: Polatuzumab Vedotin
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT04690322
Drug: Eloctate
Normalized name: Eloctate
DrugBank: Efmoroctocog alfa (DB11607)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Eloctate is FDA-approved to treat patients with Hemophilia A. This drug will be used for extended half-life factor VIII-based replacement therapy.
Study: NCT04690322
Drug: Adynovate
Normalized name: Adynovate
DrugBank: PEGylated Recombinant Factor VIII (DB16093)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adynovate is FDA-approved to treat patients with Hemophilia A. This drug will be used for extended half-life factor VIII-based replacement therapy.
Study: NCT04690322
Drug: Emicizumab
Normalized name: Emicizumab
DrugBank: Emicizumab (DB13923)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Emicizumab is FDA-approved to treat patients with Hemophilia A. This drug will be used for non-factor VIII-based replacement therapy.
Study: NCT06331559
Drug: SIM0501 in combination with olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Every 28 days is one cycle.Multiple dose levels of SIM0501 and olaparib will be explored in dose escalation, and determine the maximum tolerated dose.
Study: NCT06331559
Drug: SIM0501 in combination with olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Every 28 days is one cycle.Patients will be administered a potential recommended dose of SIM0501 combination with olaparib established from SIM0501 combination dose escalation.
Study: NCT05597202
Drug: Semaglutide, 2.0 mg/mL
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Semaglutide 2.0 mg/mL, administered subcutaneously once per week for a period of 6 months.